Company intelligence / Profile preview

China West

Chengdu, Sichuan, China

Ownership: Private
Employees: ~500
Development stage: Other

Overview

WestVac Biopharma is a clinical-stage biotechnology company based in Chengdu, China, specializing in the development of innovative vaccines and immunotherapy. Spun off from West China Hospital of Sichuan University, the company gained global prominence for developing the first insect-cell-produced recombinant protein COVID-19 vaccine (Coviccin). Its pipeline includes various next-generation COVID-19 vaccines targeting variants like XBB and Delta, as well as candidates for other infectious diseases and oncology. WestVac leverages a robust insect cell expression platform and advanced adjuvant technologies to produce scalable and effective vaccine solutions.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

West China HospitalSichuan University

Beyond the preview

Go deeper on China West.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China West.

Explore the full profile